ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacituzumab govitecan

Also written as “Sacituzumab Govitecan-hziy”, “Sacituzumab Govitecan” and “Sacituzumab Govitecan-hziy (SG)”.

Its studies are mostly in Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Transitional Cell · Neoplasm Metastasis, led by 2 companies.

Drug pageSacituzumab govitecan: every studyAll 102 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 19, 202024 company-led studies, 18 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only2317 open or runningphase 4since Mar 19, 2020Jun 26, 2012Dec 2026phase 1 · NCT04617522
Merck11 open or runningphase 3since Nov 2, 2022Nov 2, 2022Jan 12, 2027phase 3 · NCT05609968

Also a collaborator on its studies: Pfizer, Merck KGaA, Darmstadt, Germany and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named sacituzumab govitecanINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Nov 2, 2022First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05609968 · 614 enrolled · United States, Australia, Brazil and more

Ahead

  1. Jan 12, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05609968

TargetBeta

TACSTD2 →read by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05609968Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingJan 12, 2027614

How it is read

Names in the registry

  • “Sacituzumab Govitecan-hziy”, 12 entries
  • “Sacituzumab Govitecan”, 4 entries
  • “Sacituzumab Govitecan-hziy (SG)”, 4 entries
  • “Sacituzumab govitecan-hziy (SG)”, 2 entries
  • “Sacituzumab Govitecan (SG)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.